by Rod Raynovich | Apr 20, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Tech Goes from Laggard to Leader Taking Strong Biotech Sector Along for the Ride Tech stocks rallied big today with the NASDAQ up 2.1% to 2802, The Dow hit a new 2 1/2 year high up 1.5% to 12,453.The main catalyst was Intel (INTC $21.41) up 7.4% beating EPS estimates...
by Rod Raynovich | Apr 19, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Markets stabilized today with major indices up in the 0.4% range. Despite some weakness in meteoric biopharma stocks the healthcare sector is catching bids. Unloved and unwanted Johnson and Johnson(JNJ $61.87) is trying to shake off product quality issues up 2.33%,...
by Rod Raynovich | Apr 18, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Even the biotech bulls bailed today on the double whammy of concern about Europe’s debt crisis and the S&P echoing the Tea Party refrain about the U.S. budget deficit and need for fiscal reform. As of mid-day trading both the S&P 500 and the NASDAQ is...
by Rod Raynovich | Apr 15, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Drug and Biotechnology Stocks Up Across the Spectrum Its “groundhog day” in biotech world. Apparently money that has come out of tech stocks and money markets is going into healthcare stocks. In case you missed it even large cap drug stocks which have...
by Rod Raynovich | Apr 14, 2011 | BIOgraph, Reading List
This was published today on www.InvestorUprising.com. Biotech stocks are up 10% YTD. Investor Uprising – Rod Raynovich – The Biggest Biotech Trends
by Rod Raynovich | Apr 14, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biotech stocks are up again today ignoring the overall weakness in tech stocks. Among the notable movers today are: Dendreon (DNDN $41.15) broke out above 40 up 5.5% on heavy volume with high expectations for the May 2 Conference call and presentation of data at ASCO...
by Rod Raynovich | Apr 12, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biotechnology Sector Outperforming Within NASDAQ A torrid run-up of over 10% in biotech stocks over the past 3 weeks brings caution to mind as the NASDAQ sell-off hits 1%. Over the past 5 days the NASDAQ sell-off is 2% while biotech indices are only down 1%,...
by Rod Raynovich | Apr 12, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Exelixis (EXEL $12.17) has hired Goldman-Sachs to deal with potential takeover bids according to stories in Reuters and Bloomberg. Exelixis has a Phase III cancer drug XL184 (cabozantinab) and announced positive Phase 2 interim data for prostate cancer on Feb. 17....
by Rod Raynovich | Apr 11, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biogen (BIIB $78.24) soared today on positive top line data on the Phase 3 Trial for oral BG-12 (dimethyl fumarate) as a montherapy in people with relapsing-remitting multiple sclerosis (RRMS). Results showed that 240 mg of BG-12 2x or 3x a day met the primary and...
by Rod Raynovich | Apr 8, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Reviewing Today’s Action A mixed market today with a slight edge to the bulls. Immunogen(IMGN $12.28) up 4% continues its run from yesterday on positive data from its collboration with Roche on T-DM1 (trastuzumab) an antibody coupled with a cell killing agent...
